C
Capivasertib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Capivasertib
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended capivasertib in combination with fulvestrant for inclusion on the MOH List of Subsidised Drugs for HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration following disease recurrence or progression on or after an endocrine-based regimen with or without a cyclin-dependant kinase 4/6 inhibitor (CDK4/6i). The decision was based on the uncertain extent of clinical benefit compared with fulvestrant monotherapy, unfavourable cost effectiveness compared with alternative treatments, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for capivasertib are provided in the Annex.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.